Therapy Areas: Inflammatory Diseases
Physiomics secures follow-on UK contract for Phase 2 study support
15 December 2025 - Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, announced on Monday that it has been awarded a follow-on contract with an existing UK cl...
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
15 December 2025 - Biopharmaceutical company RedHill Biopharma Ltd (Nasdaq: RDHL) on Monday reported positive in vivo results showing that opaganib, when combined with venetoclax, reduced Chronic Lymp...
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
10 December 2025 - Biotechnology company InduPro Inc announced on Wednesday that it has entered into a strategic equity investment and research collaboration with French healthcare company Sanofi S.A....
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
10 December 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Tuesday that that the first participant has been dosed in the Phase 1 clinical trial of IBI3011, a...
LabGenius and Sanofi launch AI-driven collaboration on antibody optimisation
4 December 2025 - Drug discovery company LabGenius Therapeutics announced on Thursday a new collaboration with French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) to optimise thera...
Mitsubishi Tanabe Pharma America changes name
2 December 2025 - Mitsubishi Tanabe Pharma America Inc (MTPA), a subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC), announced on Monday that it has changed its corporate name to Ta...